Cover of: Disodium pamidronate (APD) in the treatment of malignancy-related disorders | European Society for Medical Oncology. Congress. Read Online
Share

Disodium pamidronate (APD) in the treatment of malignancy-related disorders an international symposium held during the 13th Congress of the European Society for Medical Oncology (ESMO), Lugano, Switzerland, October 1988 by European Society for Medical Oncology. Congress.

  • 874 Want to read
  • ·
  • 17 Currently reading

Published by Hogrefe & Huber in Toronto, Lewiston, N.Y .
Written in English

Subjects:

  • Bones -- Tumors -- Chemotherapy -- Congresses.,
  • Disodium pamidronate -- Therapeutic use -- Congresses.,
  • Hypercalcemia -- Chemotherapy -- Congresses.,
  • Bone resorption -- Chemotherapy -- Congresses.,
  • Cancer -- Adjuvant treatment -- Congresses.,
  • Diphosphonates -- Therapeutic use -- Congresses.,
  • Bones Neoplasms -- secondary -- congresses.,
  • Diphosphonates -- therapeutic use -- congresses.,
  • Hypercalcemia -- drug therapy -- congresses.

Book details:

Edition Notes

Includes bibliographical references.

StatementPeter Burckhardt, editor.
ContributionsBurckhardt, Peter.
Classifications
LC ClassificationsRC280.B6 E97 1988
The Physical Object
Pagination138 p. :
Number of Pages138
ID Numbers
Open LibraryOL2196034M
ISBN 100920887570, 3456818254
LC Control Number89015616

Download Disodium pamidronate (APD) in the treatment of malignancy-related disorders

PDF EPUB FB2 MOBI RTF

How to use Pamidronate DISODIUM Vial. This medication is given by slow injection into a vein for at least 2 hours, but up to 24 hours, or as directed by your doctor.. The dosage is based on your. Instruct patient to inform health care professional of pamidronate therapy priortodentalsurgery. Emphasize the need for keeping follow-up exams to monitor progress, even afterFile Size: KB. DISODIUM PAMIDRONATE. Other names: APD, or AHPrBP (Aminohydroxypropylidene bisphosphonate disodium) Pamidronate, Aredia. Action: Inhibiting bone resorption with apparently minimal effect on .   Pamidronate disodium binds to bone and reduces the rate at which it is broken down. This helps strengthen bones by preventing the loss of calcium and this reduces the high levels of calcium in the blood. In Paget's disease of bone, pamidronate disodium .

  The recommended dose of disodium pamidronate for the treatment of predominantly lytic bone metastases and multiple myeloma is 90mg administered as a single infusion every 4 weeks. In patients with bone metastases who receive chemotherapy at 3-weekly intervals, disodium pamidronate . For slow intravenous infusion (Pamidronate disodium, Hospira, Medac, Wockhardt), give intermittently in Glucose 5% or Sodium chloride %; give at a rate not exceeding 1 mg/minute; not to be given with infusion fluids containing calcium.. For Pamidronate disodium .   Pamidronate disodium is a white-to-practically-white powder. It is soluble in water and in 2N sodium hydroxide, sparingly soluble in N hydrochloric acid and in N acetic acid, and .   Pamidronate is a bisphosphonate (bis FOS fo nayt) medicine that alters bone formation and breakdown in the body. This can slow bone loss and may help prevent bone fractures. Pamidronate is used to treat Paget's disease of bone. Pamidronate .

  Material Name: Pamidronate Disodium Injection (Hospira, Inc.) Molecular Weight: Mixture Slovakia OEL - TWA 2 mg/m3 Version: Page 5 of 10 Slovenia OEL - TWA 2 mg/m3 Latvia . Pamidronate Disodium is the disodium salt of the synthetic bisphosphonate gh its mechanism of action is not completely understood, pamidronate appears to adsorb to calcium . More About Pamidronate Disodium. Definition from the NCI Drug Dictionary - Detailed scientific definition and other names for this drug. MedlinePlus Information on Pamidronate Disodium - A lay . Vials - 30 mg - each contains 30 mg of sterile, lyophilized pamidronate disodium and mg of mannitol, USP. Carton of 4 vials NDC Vials - 90 mg - each contains 90 mg of sterile, lyophilized pamidronate disodium .